Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab (vol 115, pg 71, 2018)

被引：3
|
作者：
Sato, Koichi [1 ]
Akamatsu, Hiroaki [1 ]
Murakami, Eriko [1 ]
Sasaki, Seigo [1 ]
Kanai, Kuninobu [1 ]
Hayata, Atsushi [1 ]
Tokudome, Nahomi [1 ]
Akamatsu, Keiichiro [1 ]
Koh, Yasuhiro [1 ]
Ueda, Hiroki [1 ]
Nakanishi, Masanori [1 ]
Yamamoto, Nobuyuki [1 ]
机构：
[1] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
来源：
LUNG CANCER | 2018年 / 126卷
关键词：
D O I：
10.1016/j.lungcan.2018.11.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [31] Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
    Naqash, Abdul Rafeh
    Ricciuti, Biagio
    Owen, Dwight H.
    Florou, Vaia
    Toi, Yukihiro
    Cherry, Cynthia
    Hafiz, Maida
    De Giglio, Andrea
    Muzaffar, Mavish
    Patel, Sandip H.
    Sugawara, Shunichi
    Burkart, Jarred
    Park, Wungki
    Chiari, Rita
    Sugisaka, Jun
    Otterson, Gregory A.
    de Lima Lopes, Gilberto
    Walker, Paul R.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (07) : 1177 - 1187
  • [32] Immune-related adverse events in non-small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
    Lin, Xuwen
    Xie, Mei
    Yao, Jie
    Ma, Xidong
    Qin, Lin
    Zhang, Xu-Mei
    Song, Jialin
    Bao, Xinyu
    Zhang, Xin
    Zhang, Yinguang
    Liu, Yiming
    Han, Wenya
    Liang, Yiran
    Jing, Ying
    Xue, Xinying
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (03):
  • [33] Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer
    Thompson, Leah L.
    Nadelmann, Emily R.
    Blum, Amy E.
    Yoon, Jaewon
    Polyakov, Nicole J.
    Kagan, Ruth D.
    Gainor, Justin F.
    Mooradian, Meghan J.
    Chen, Steven T.
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 13 - 16
  • [34] Association between immune-related adverse events and microbiome composition in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Tonneau, Marion
    Richard, Corentin
    Nolin-Lapalme, Alexis
    Auclin, Edouard
    Benlaifaoui, Myriam
    Ponce, Mayra
    Al-Saleh, Afnan
    Blais, Normand
    Florescu, Marie
    Tehfe, Mustapha
    Malo, Julie
    Messaoudene, Meriem
    Okuma, Yusuke
    Hakozaki, Taiki
    Routy, Bertrand
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer
    Hayashi, Hidetoshi
    Nishio, Makoto
    Akamatsu, Hiroaki
    Goto, Yasushi
    Miura, Satoru
    Gemma, Akihiko
    Yoshino, Ichiro
    Misumi, Toshihiro
    Kijima, Takashi
    Takase, Naoto
    Fujita, Masaki
    Tasaka, Sadatomo
    Mouri, Atsuto
    Kondo, Tetsuro
    Takamura, Kei
    Kawashima, Yosuke
    Imaizumi, Kazuyoshi
    Iwasawa, Shunichiro
    Nakagawa, Shintaro
    Mitsudomi, Tetsuya
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (11): : 2858 - 2867
  • [36] The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer (vol 41, pg 347, 2021)
    Bredin, Philip
    Naidoo, Jarushka
    CANCER AND METASTASIS REVIEWS, 2024, 43 (02) : 865 - 865
  • [37] Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab
    Bouhlel, Linda
    Doyen, Jerome
    Chamorey, Emmanuel
    Poudenx, Michel
    Ilie, Marius
    Gal, Jocelyn
    Guigay, Joel
    Benzaquen, Jonathan
    Marquette, Charles-Hugo
    Berthet, Jean-Philippe
    Mouroux, Jerome
    Schiappa, Renaud
    Padovani, Bernard
    Hofman, Paul
    Otto, Josiane
    BULLETIN DU CANCER, 2020, 107 (09) : 946 - 958
  • [38] The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis
    Sonehara, Kei
    Tateishi, Kazunari
    Araki, Taisuke
    Komatsu, Masamichi
    Yamamoto, Hiroshi
    Koizumi, Tomonobu
    Hanaoka, Masayuki
    ONCOLOGY, 2021, 99 (05) : 271 - 279
  • [39] Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
    Shankar, Bairavi
    Zhang, Jiajia
    Naqash, Abdul Rafeh
    Forde, Patrick M.
    Feliciano, Josephine L.
    Marrone, Kristen A.
    Ettinger, David S.
    Hann, Christine L.
    Brahmer, Julie R.
    Ricciuti, Biagio
    Owen, Dwight
    Toi, Yukihiro
    Walker, Paul
    Otterson, Gregory A.
    Patel, Sandip H.
    Sugawara, Shunichi
    Naidoo, Jarushka
    JAMA ONCOLOGY, 2020, 6 (12) : 1952 - 1956
  • [40] The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
    Philip Bredin
    Jarushka Naidoo
    Cancer and Metastasis Reviews, 2022, 41 : 347 - 366
12345